Vusolimogene oderparepvec-wtpg
Vusolimogene oderparepvec-wtpg (Tudriqev) is a genetically modified herpes simplex virus, type 1 (HSV-1) oncolytic viral therapy designed to replicate in cancer cells and produce a protein聽called聽GM-CSF聽(granulocyte-macrophage colony-stimulating factor).It is indicated in combination with the checkpoint inhibitor nivolumab (Opdivo), which is an anti-programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1, a checkpoint control.
Vusolimogene oderparepvec-wtpg in combination with nivolumab is indicated for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a PD-1-blocking antibody-based regimen.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response. Continued approval for this indication may becontingent upon verification of clinical benefit in confirmatory trial(s).
Provider Resource
